Microbot Medical signs three-year exclusive distribution deal for LIBERTY system in Israel

Microbot Medical (Nasdaq: MBOT) reported Q2 2026 revenue and new-customer growth of more than 100% vs Q1 2026, citing the LIBERTY System’s full market release on April 13. The company says procedure volumes rose at prior limited-release sites, expanded U.S. sales territories from 4 to 8 (target 12 by year-end), added a federal-services agreement, and received Israeli marketing clearance.

Viking Therapeutics (VKTX) presented clinical data from its VK2735 obesity program at ObesityWeek 2026. In a Phase 2 trial, 74% of participants improved by at least one BMI category after 13 weeks, with significant reductions in cardiometabolic markers. The company also shared baseline data from its ongoing Phase 3 VANQUISH-2 study. VK2735 is a dual GLP-1 and GIP receptor agonist being developed for obesity and metabolic disorders.

Nvidia announced CEO Jensen Huang's resignation and departure from the board. Colette Kress, the CFO, is interim CEO. The company thanked Huang for his contributions. No reason was given, but speculation links it to his personal scandal and national security concerns. The FBI is investigating alleged Nvidia chip exports to China via Megaspeed, where Alice Huang, tied to Jensen, is an executive. This could impact US-China relations and AI competition.

Mizuho upgraded Viking Holdings (VIK) to Outperform, raising its price target to $120. The firm cited normalized valuation and transitory river level issues in Europe. VIK's stock is down 16% in three months but up 52% over a year. Analysts expect Q3 earnings to be a catalyst, with varied price targets from UBS, Stifel, and Barclays.

CVS Health (CVS) published research showing GLP-1 drugs improve health outcomes and reduce medical costs, but savings don't cover pharmacy expenses at current prices. The company suggests treating the right patients, ensuring therapy adherence, and lowering drug prices for better value. CVS stock has seen recent price target adjustments and analyst commentary.

SpaceX (SPCX) shares closed at $139.11, near their IPO price of $135, after a 0.6% drop. The company achieved a milestone by catching its Starship rocket's upper stage post-market. Shares have been volatile, influenced by Tesla merger speculation and AI sector trends. Analysts remain mostly optimistic, with average price targets around $250-$265, though risks include high valuation and heavy spending.